Results from a clinical trial showed that capivasertib plus the hormone therapy fulvestrant increased the time before the ...

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for VITRAKVI® (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and pediatric ...

The biological research of UC Santa Cruz's Needhi Bhalla to determine the molecular motions at the heart of heredity has yielded a new discovery: The proper transfer of genetic materials depends on ...

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, announced today that it has ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...